MedTrace Logo

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

NCT04756765 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-08-17

No results posted yet for this study

Summary

This purpose of this study is to test if talazoparib is safe and evaluate its response to advanced breast cancer associated with mutation of gene called PALB.

Conditions

Interventions

DRUG

Talazoparib Tosylate

Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.

Sponsors & Collaborators

Principal Investigators

  • Melinda Telli · Stanford Universiy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-23
Primary Completion
2024-12-18
Completion
2024-12-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04756765 on ClinicalTrials.gov